KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Return on Sales (2017 - 2025)

Moderna (MRNA) has disclosed Return on Sales for 9 consecutive years, with 1.22% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales fell 26.0% to 1.22% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.45%, a 40.0% decrease, with the full-year FY2025 number at 1.45%, down 35.0% from a year prior.
  • Return on Sales was 1.22% for Q4 2025 at Moderna, down from 0.2% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.68% in Q4 2021 to a low of 8.99% in Q1 2025.
  • A 5-year average of 1.65% and a median of 0.02% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: surged 1613bps in 2021, then plummeted -708bps in 2024.
  • Moderna's Return on Sales stood at 0.68% in 2021, then plummeted by -57bps to 0.29% in 2022, then tumbled by -73bps to 0.08% in 2023, then plummeted by -1342bps to 0.96% in 2024, then dropped by -27bps to 1.22% in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Return on Sales are 1.22% (Q4 2025), 0.2% (Q3 2025), and 5.81% (Q2 2025).